Author

Ruth E. Mauntz

Observed names: Mauntz, Ruth, Ruth Mauntz

Institution: Grail (United States)

Observed institutions: San Diego State University, Grail (United States), Expression Drug Designs (United States)

ORCID: 0000-0003-0376-3313

Observed ORCID: 0000-0003-0376-3313

OpenAlex ID: A5015020441

A comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-specific biomarkers for cancer detection

2021 · Matthew H. Larson, Wenying Pan, et al. · Nature Communications · 256

Using Drosophila as an integrated model to study mild repetitive traumatic brain injury

2016 · Ayeh Barekat, Arysa Gonzalez, et al. · Scientific Reports · 87

Up in Arms: Immune and Nervous System Response to Sea Star Wasting Disease

2015 · Lauren E. Fuess, Morgan E. Eisenlord, et al. · PLoS ONE · 60

Aging and Autophagic Function Influences the Progressive Decline of Adult Drosophila Behaviors

2015 · Eric P. Ratliff, Ruth E. Mauntz, et al. · PLoS ONE · 40

Aging and Intermittent Fasting Impact on Transcriptional Regulation and Physiological Responses of Adult Drosophila Neuronal and Muscle Tissues

2018 · Sharon Zhang, Eric Ratliff, et al. · International Journal of Molecular Sciences · 23

Assessing Basal and Acute Autophagic Responses in the Adult Drosophila Nervous System: The Impact of Gender, Genetics and Diet on Endogenous Pathway Profiles

2016 · Eric P. Ratliff, Roxanne W. Kotzebue, et al. · PLoS ONE · 16

Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non–small cell lung cancer: KEYNOTE-782

2024 · Jair Bar, Emilio Esteban, et al. · Lung Cancer · 7

Author Correction: A comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-specific biomarkers for cancer detection

2022 · Matthew H. Larson, Wenying Pan, et al. · Nature Communications · 6

Abstract LB107: Association of circulating free DNA (cfDNA) maximum variant allele frequency (mVAF) levels with clinical outcomes in patients (pts) with metastatic nonsquamous non-small cell lung cancer (NSCLC) treated with pembrolizumab (pembro) + chemotherapy (chemo) in the phase 2 KEYNOTE-782 trial

2024 · Jair Bar, Emilio Esteban, et al. · Cancer Research

Abstract CT216: Response to first-line (1L) pembrolizumab (pembro) + chemotherapy (chemo) in non-small cell lung cancer (NSCLC) by blood tumor mutational burden (bTMB): the phase 2 KEYNOTE-782 trial

2023 · Jair Bar, Emilio Esteban, et al. · Cancer Research

Works count: 12

Citation count: 496

H-index: 7

I10-index: 6